A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971)

Exclusion Criteria

• •Participants in whom a difficult intubation because of anatomical malformations was expected;
• •Is known or suspected to have neuromuscular disorders impairing neuromuscular blocking (NMB) and/or significant renal dysfunction (for example a creatinine level \> 1.6 mg/dl) and/or severe hepatic dysfunction.
• •Is known or suspected to have a (family) history of malignant hyperthermia;
• •Is known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia;
• •Is receiving medication expected to interfere with the rocuronium or vecuronium given in this trial, based on the dose and time of administration;
• •Females who were pregnant;
• •Females of childbearing potential not using birth control or using only oral contraception as birth control;
• •Was breast-feeding;
• •Has already participated in P05971, or in another trial with sugammadex;
• •Has participated in another clinical trial, not preapproved by the Sponsor, within 6 months of entering into P05971.